Credit Suisse’s Regeneron Pharmaceuticals REGN Stock Holding History

Credit Suisse’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,200	Closed	-$3.28M	–	4191
2021 Q4	$3.28M	Sell	5,200 -4,600	-47%	-$2.83M	﹤0.01%	2376
2021 Q3	$5.93M	Buy	9,800 +6,300	+180%	+$3.91M	﹤0.01%	1921
2021 Q2	$1.96M	Sell	3,500 -3,400	-49%	-$1.72M	﹤0.01%	2885
2021 Q1	$3.27M	Sell	6,900 -13,600	-66%	-$6.62M	﹤0.01%	2448
2020 Q4	$9.9M	Hold	20,500	–	–	﹤0.01%	1585
2020 Q3	$11.5M	Sell	20,500 -29,900	-59%	-$18.1M	0.01%	1301
2020 Q2	$31.4M	Buy	50,400 +20,000	+66%	+$11.4M	0.02%	731
2020 Q1	$14.8M	Sell	30,400 -16,700	-35%	-$6.89M	0.01%	979
2019 Q4	$17.7M	Hold	47,100	–	–	0.01%	1102
2019 Q3	$13.1M	Sell	47,100 -19,500	-29%	-$5.77M	0.01%	1159
2019 Q2	$20.8M	Buy	66,600 +56,300	+547%	+$18.7M	0.02%	903
2019 Q1	$4.23M	Buy	+10,300	New	+$4.24M	﹤0.01%	1846

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Credit Suisse's REGN Position: Q1 2024 in Review

Credit Suisse reduced its Regeneron Pharmaceuticals (REGN) stake by 5.7% in Q1 2024, selling an estimated $9.51M and leaving 165,324 shares worth $159M. The position accounts for 0.15% of the portfolio, ranked #115.

Credit Suisse first reported a position in REGN in Q2 2013 and has held it in 44 quarters since. The position peaked at $271M in Q1 2021. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Credit Suisse held 165,324 shares of Regeneron Pharmaceuticals worth $159M as of Q1 2024.
Credit Suisse sold 10,004 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $9.51M.
Regeneron Pharmaceuticals made up 0.15% of Credit Suisse's portfolio in Q1 2024, its #115 holding.
Credit Suisse first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's Regeneron Pharmaceuticals position peaked at $271M in Q1 2021.
1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.